Gennex Laboratories Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹7.6
- Today's High:
- ₹8.03
- Open Price:
- ₹7.97
- 52W Low:
- ₹4.81
- 52W High:
- ₹9.2
- Prev. Close:
- ₹7.97
- Volume:
- 292118
Company Statistics
- Market Cap.:
- ₹473.12 million
- Book Value:
- 2.82
- Revenue TTM:
- ₹529.96 million
- Operating Margin TTM:
- 4.31%
- Gross Profit TTM:
- ₹222.67 million
- Profit Margin:
- 2.69%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Gennex Laboratories Limited had its IPO on under the ticker symbol 531739.
The company operates in the Healthcare sector and Drugs - Generic industry. Gennex Laboratories Limited has a staff strength of 95 employees.
Stock update
Shares of Gennex Laboratories Limited opened at ₹7.97 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹7.6 - ₹8.03, and closed at ₹7.82.
This is a -1.88% slip from the previous day's closing price.
A total volume of 292,118 shares were traded at the close of the day’s session.
In the last one week, shares of Gennex Laboratories Limited have slipped by -2.49%.
Gennex Laboratories Limited's Key Ratios
Gennex Laboratories Limited has a market cap of ₹473.12 million, indicating a price to book ratio of 1.2909 and a price to sales ratio of 0.8789.
In the last 12-months Gennex Laboratories Limited’s revenue was ₹529.96 million with a gross profit of ₹222.67 million and an EBITDA of ₹32.91 million. The EBITDA ratio measures Gennex Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Gennex Laboratories Limited’s operating margin was 4.31% while its return on assets stood at 0% with a return of equity of 0%.
In Q2, Gennex Laboratories Limited’s quarterly earnings growth was a negative -53.2% while revenue growth was a negative 19.7%.
Gennex Laboratories Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 32.2124
- PEG
Its diluted EPS in the last 12-months stands at ₹0.113 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Gennex Laboratories Limited’s profitability.
Gennex Laboratories Limited stock is trading at a EV to sales ratio of 0.9655 and a EV to EBITDA ratio of 13.9194. Its price to sales ratio in the trailing 12-months stood at 0.8789.
Gennex Laboratories Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹1.32 billion
- Total Liabilities
- ₹295.13 million
- Operating Cash Flow
- ₹-383734000.00
- Capital Expenditure
- ₹397.86 million
- Dividend Payout Ratio
- 0%
Gennex Laboratories Limited ended 2024 with ₹1.32 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.32 billion while shareholder equity stood at ₹803.50 million.
Gennex Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹295.13 million in other current liabilities, 180193000.00 in common stock, ₹623.31 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹145.01 million and cash and short-term investments were ₹150.64 million. The company’s total short-term debt was ₹10,536,000 while long-term debt stood at ₹162.88 million.
Gennex Laboratories Limited’s total current assets stands at ₹486.83 million while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹94.17 million compared to accounts payable of ₹0 and inventory worth ₹156.93 million.
In 2024, Gennex Laboratories Limited's operating cash flow was ₹-383734000.00 while its capital expenditure stood at ₹397.86 million.
Comparatively, Gennex Laboratories Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹7.82
- 52-Week High
- ₹9.2
- 52-Week Low
- ₹4.81
- Analyst Target Price
- ₹
Gennex Laboratories Limited stock is currently trading at ₹7.82 per share. It touched a 52-week high of ₹9.2 and a 52-week low of ₹9.2. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹7.62 and 200-day moving average was ₹6.53 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 2201.9% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Gennex Laboratories Limited
Similar Industry Stocks (Drugs - Generic)
Most Active
Top Gainers
Top Losers
About
Gennex Laboratories Limited engages in the manufacturing and selling of bulk drugs, intermediates, and biotech products in India and internationally. The company offers active pharmaceutical ingredients, including Guaifenesin; Methocarbamol; Fluconazole; Phenazopyridine Hcl; Allopurinol; and Ketoconazole. Its pipeline products include Melitracen Hydrochloride; Flupentixol Di-Hydrochloride; Domperidone; Potassium Guaiacol Sulphonate; Mefenamic Acid; Melitracen; and Chlorphenesin. The company was formerly known as Prudential Pharmaceuticals Limited. Gennex Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.